TW497972B - Stable thrombopoietin (TPO)-containing lyophilized compositions - Google Patents

Stable thrombopoietin (TPO)-containing lyophilized compositions Download PDF

Info

Publication number
TW497972B
TW497972B TW084106390A TW84106390A TW497972B TW 497972 B TW497972 B TW 497972B TW 084106390 A TW084106390 A TW 084106390A TW 84106390 A TW84106390 A TW 84106390A TW 497972 B TW497972 B TW 497972B
Authority
TW
Taiwan
Prior art keywords
leu
freeze
pro
thr
ctg
Prior art date
Application number
TW084106390A
Other languages
English (en)
Chinese (zh)
Inventor
Hideaki Nomura
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of TW497972B publication Critical patent/TW497972B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/196Thrombopoietin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW084106390A 1995-06-08 1995-06-21 Stable thrombopoietin (TPO)-containing lyophilized compositions TW497972B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14207595 1995-06-08

Publications (1)

Publication Number Publication Date
TW497972B true TW497972B (en) 2002-08-11

Family

ID=15306858

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084106390A TW497972B (en) 1995-06-08 1995-06-21 Stable thrombopoietin (TPO)-containing lyophilized compositions

Country Status (8)

Country Link
EP (1) EP0841066A1 (enExample)
KR (1) KR19990022398A (enExample)
CN (1) CN1192691A (enExample)
AU (1) AU5911796A (enExample)
CA (1) CA2223749A1 (enExample)
MX (1) MXPA97009801A (enExample)
TW (1) TW497972B (enExample)
WO (1) WO1996041642A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4344697A (en) * 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
CN111588841A (zh) * 2019-02-21 2020-08-28 中国人民解放军军事科学院军事医学研究院 一种可气溶胶化的seb类毒素疫苗干粉吸入剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
WO1990012108A1 (en) * 1989-04-03 1990-10-18 Genetics Institute, Inc. Megakaryocyte growth promoting activity
EP0499242B1 (en) * 1991-02-15 1996-06-26 Takeda Chemical Industries, Ltd. Stimulation of endosteal bone formation with a cell growth factor
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
AU1843595A (en) * 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
PL178384B1 (pl) * 1994-02-14 2000-04-28 Univ Washington Wydzielone białko, wydzielone cząsteczki polinukleotydowe, wektor ekspresji, hodowana komórka, kompozycja farmaceutyczna do stymulacji wytwarzania płytek krwi u ssaka, sposób wytwarzania białka homeopoezyjnego, sposób otrzymywania przeciwciał, sposób stymulacji i namnażania komórek
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions

Also Published As

Publication number Publication date
AU5911796A (en) 1997-01-09
EP0841066A4 (enExample) 1998-06-03
EP0841066A1 (en) 1998-05-13
CN1192691A (zh) 1998-09-09
CA2223749A1 (en) 1996-12-27
MXPA97009801A (es) 2003-10-30
KR19990022398A (ko) 1999-03-25
WO1996041642A1 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
JP2541761B2 (ja) ミュレル管抑制物質様ポリペプチドおよびその製造方法
Francis et al. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II
JPH01501283A (ja) 新規な型のコロニー刺激因子―1
JP3946638B2 (ja) 生体内エリスロポエチン活性が増強された融合蛋白質
JP2002530059A (ja) 輸送ベクター
HU211229A9 (en) Glycoprotein of human origin, physiologically active factor comprising the same, and pharmaceutical preparation containing the same as active ingredient
SK171492A3 (en) Polypeptide, method of its preparation its use and pharmaceutical agent
EP2796462B1 (en) Anti-tumor peptide and use therefor
JPH04503808A (ja) 新規インシュリン化合物
HU200793B (en) Genetic engineering technique for producing new, human interleukin-2 protein
JP3303211B2 (ja) bFGFムテインおよびその製造法
TW497972B (en) Stable thrombopoietin (TPO)-containing lyophilized compositions
EP2742064B1 (en) Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
KR101346499B1 (ko) 재조합 이합체 생식샘자극호르몬의 산화 형 준위를 감소시키기 위한 무혈청 배양 배지
Lee et al. The prolonged half-lives of new erythropoietin derivatives via peptide addition
JP2000504561A (ja) Il―16活性のあるポリペプチド類、その製造方法およびその使用
JPH07507328A (ja) Tcf変異体
Boumaiza et al. Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1
US5656458A (en) Expression and processing of amino terminus acetylated FGF's in yeast
TW420688B (en) Mpl ligand analogs
IE914484A1 (en) Oxidation resistant variants of parathyroid hormone
CA2002210C (en) Expression and processing of authentic fgf's in yeast
JP2619036B2 (ja) ブタ成長ホルモンアナログ
Su et al. High-level expression of human stem cell factor fused with erythropoietin mimetic peptide in Escherichia coli
EP0613946A2 (en) hst-2 Mutein, DNA coding for the same and preparation thereof

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent